[Hong Kong, September 18, 2021] Recently, Mr. Kingsley Leung, Chairman of Great Bay Bio Holdings Limited (hereinafter referred to as “GBB”), was recognized as one of the ten Gen.T X Credit Suisse Social Impact Awardees of the year 2021 in the fields of innovation and Gen.T  Leader of Tomorrow 2021 for his contribution to biotech industry.

The 2021 China Social Impact Award and Leader of Tomorrow aim to commend and praise the efforts and achievements of enterprises from all walks of life and various scales for the positive impact of Chinese society as well as the environment, and to encourage and improve the sense of responsibility of Chinese enterprises. The awards encourage companies and individuals to make positive changes and impacts on society, and brings together individuals and companies in the community to share ideas, experiences and methods that are condusive to society. Mr. Kingsley Leung, chairman of GBB, awarded these two honors, which is not only the affirmation of his long-term influence on society, but also the recognition of GBB's progresses under his strong leadership.

Given the wrath of pandemic, Mr. Kingsley Leung led GBB to apply the cutting-edge AI technology to bio-pharmaceutical industry, and guided GBB in financing, R&D, production, sales, business cooperation and other crucial works indispensable for company growth. With strong leadership and veteran team at GBB's disposal,   three self-developed AI-enabled CMC platforms were born. Three AI-enabled CMC platforms have all been made commercially available, solving many key pain points in the drug development process such as low success rate, long cycle, and high cost, making global bioprocessing simpler and more efficient. In addition, Mr. Kingsley Leung also awarded the Young Industrialist Awards of Hong Kong 2020. Thanks to Mr. Kingsley Leung’s great social influence and the innovation ability of the GBB team, GBB has successfully entered Hong Kong Science Park in 2021.

Mr. Chibo Tang, Managing Partner of Gobi Partners (GP of AEF) (left) and Mr. Kingsley Leung, Co-Founder of GBB (right), Signing the Investment Agreement

Mr. Kingsley Leung, Chairman of GBB, accepting the Young Industrialist Awards of Hong Kong 2020 from Mrs Carrie Lam, Chief Executive of Hong Kong

Under the leadership of Mr. Kingsley Leung, GBB was awarded the National High-tech Enterprise, Guangdong Doctoral Workstation, Guangdong Genetic Engineering Pharmaceutical Engineering Technology Research Center, Sprout List Top 150, Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020 and Hong Kong Service Innovation Excellence Award.

Related Reading

GBB Is Joining the HKSTP/FHKI Co-working Space Program

Great Bay Bio and Chime Biologics enter into Strategic Alliance

GBB’s Chairman Attended Youth Novation as A Supervisor

GBB Completes USD$3.8M Convertible Note Financing Led by Alibaba Hong Kong Entrepreneurs Fund

GBB Chairman Was Awarded “Young Industrialist of Hong Kong 2020”

About the 2021 China Social Impact Award

The 2021 China Social Impact Awards, in partnership with the United Nations, is a continuation of the 2019 Awards and previous CSR Awards organised by the British Chamber of Commerce in China in 2016 & 2017.

In the spirit of the United Nations Sustainable Development Goals, the awards are categorised by seven key areas of social impact: Environmental Impact, Empowerment of Women, Poverty Alleviation, Equality in Education, Employee Engagement, Community & Culture and Universal Healthcare.

Two awards will be given for each area of social impact, the first for large corporations who have made strides in their respective category, and the second for small to medium sized enterprises that have pioneered positive social impact in their own unique way. The ceremony will be attended by senior representatives of the United Nations, the Chinese government, international companies, executive committee members of the major chambers of commerce in China along with over 300 guests from all fields of business.

About GBB

Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to biopharmaceutical development and other blue ocean bio-products, ultimately solving numerous pain points of biopharmaceutical industry, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3000 m² CMC facilities which bolster advance equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation of AI-enabled bioprocessing ecosystem. To learn more, please visit http://www.greatbay-bio.com.